Golgi membrane protein 1 (GOLM1, also known as GP73 or GOLPH2) is a Type II Golgi transmembrane protein that has emerged as a critical biomarker and therapeutic target in hepatocellular carcinoma (HCC) and other solid tumors. While historically utilized for clinical diagnostics, recent therapeutic strategies target GOLM1 for its role in promoting cancer metastasis, regulating EGFR/RTK trafficking, and modulating immune evasion. Developing highly selective therapeutics requires robust reagents that preserve native post-translational modifications and conformational epitopes.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GOLM1 (GP73) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GOLM1 (GP73) ECD-Fc Recombinant Protein HEK293 Expressed (Native Glycosylation), High Purity (>95%), Endotoxin Controlled (<1 EU/μg). Sequence Verified. |
View GOLM1 Products |
| Gene Delivery | GOLM1 Promise-ORF / Lentivirus Full-length human GOLM1 ORF for stable cell line construction and surface expression validation. |
View GOLM1 Products |
| Benchmark Ab | Anti-GOLM1 Recombinant Antibody Recombinant positive control derived from clinical benchmark sequences for binding and internalization assays. |
View GOLM1 Products |
| Validator | GOLM1 siRNA Set Target-specific siRNA pool for knockdown verification in functional and specificity assays. |
View GOLM1 Products |
| Related Target A | GPC3 (Glypican-3) Synergistic oncogenic target in hepatocellular carcinoma; frequently co-expressed with GOLM1. |
View GPC3 Products |
| Related Target B | AFP (Alpha-Fetoprotein) Complementary serum biomarker and therapeutic target for liver lineage malignancies. |
View AFP Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Shedding & Soluble Decoy Interference | HEK293-expressed GOLM1 ECD proteins with precise C-terminal truncation to mimic natural secreted forms. |
| Glycosylation-Dependent Epitopes | Exclusively produced in mammalian cells (HEK293) to ensure authentic native Golgi glycosylation patterns. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies included for assay calibration. |
| Off-Target Cross-Reactivity | High-purity homolog panels and sequence-verified siRNA validation tools to rule out non-specific binding. |
Live GOLM1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic development targeting GOLM1 is transitioning from diagnostic validation to active therapeutic intervention. Given GOLM1's intracellular localization in normal tissues but high cell-surface expression and extracellular secretion in HCC, therapeutic focus is splitting between small-molecule trafficking inhibitors, antibody-drug conjugates (ADCs) targeting surface GOLM1, and CAR-T cell therapies. As first-generation diagnostic applications mature, the next wave of R&D targets GOLM1's interaction with accessory RTKs to overcome tyrosine kinase inhibitor (TKI) resistance in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugate (ADC) | Academic Institutes, Biotech Startups | Hepatocellular Carcinoma, Prostate Cancer | Internalization Assay (Requires HEK293-expressed GOLM1 ECD-Fc for binding kinetics) |
| CAR-T / Cell Therapy | Clinical-stage Cell Therapy Companies | Refractory HCC, Solid Tumors | Surface Antigen Density & Specificity (Requires Lentivirus for stable cell line construction) |
| Diagnostic ELISA / CLIA | In Vitro Diagnostic (IVD) Manufacturers | Early Liver Cancer Screening | High-affinity Antibody Pairs (Requires highly pure, native-glycosylated GOLM1 protein) |